Trial | NCT00381264  Report issue

Title

Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis
A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Multiple Sclerosis

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    nabilone ...

  • Study Participants

    23
This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to Multiple Sclerosis.
The purpose of this study is to determine the safety and efficacy of Cesamet™ in the symptomatic treatment of pain due to Multiple Sclerosis.

This is a phase IV, multi-center, open label outpatient clinical trial evaluating Cesamet™ treatment for control of pain due MS. The study has two phases: a Pretreatment Phase and a Treatment Phase.
Study Started
Sep 30
2006
Primary Completion
Oct 31
2007
Study Completion
Oct 31
2007
Last Update
Feb 15
2008
Estimate

Drug Cesamet™ (nabilone)

Criteria 

Inclusion Criteria:

Patients diagnosed with MS
Chronic daily pain present for at least 2 months.
On stable analgesic regimen for one month
Baseline pain score greater than 40mm on a visual analog scale.

Exclusion Criteria:

Hypersensitivity to compounds in study drug or similar drugs
Pregnant or lactating females
Drug or alcohol abuse
Unstable medical condition
No Results Posted